Compare LBRX & BLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | BLW |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 532.2M |
| IPO Year | N/A | N/A |
| Metric | LBRX | BLW |
|---|---|---|
| Price | $24.14 | $13.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 180.1K | 85.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.81 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $12.35 |
| 52 Week High | $24.95 | $14.26 |
| Indicator | LBRX | BLW |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 51.45 |
| Support Level | $23.52 | $13.70 |
| Resistance Level | $24.84 | $13.84 |
| Average True Range (ATR) | 1.58 | 0.05 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 81.96 | 56.25 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.